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Abstract
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Porcine reproductive and respiratory syndrome (PRRS) causes significant economic losses to the
swine industry worldwide. Although inactivated and live vaccines are commercially available for
the control of PRRS, both types of vaccine have not always proven successful in terms of
generating a protective immune response, particularly in the case of inactivated vaccines. In this
study, we tested whether an inactivated vaccine could induce a humoral immune response to
PRRS during a homologous challenge. Amino acid substitutions were introduced into
glycoprotein (GP) 5 of the FL12 strain of the PRRS virus (PRRSV) using site-directed
mutagenesis with a pFL12 infectious clone. The substitutions led to double deglycosylation in the
putative glycosylation moieties on GP5. The mutant virus was subsequently inactivated with
binary ethylenimine. The efficacy of the inactivated mutant virus was compared with that of the
inactivated wild-type PRRSV. Only the inactivated mutant PRRSV induced serum neutralizing
antibodies at six weeks post-vaccination. The group that was administered the inactivated mutant
virus twice exhibited a significantly increased neutralizing antibody titer after a challenge with the
virulent homologous strain and exhibited more rapid clearing of viremia compared to other
groups, including the groups that were administered either the inactivated mutant or wild-type
virus only once and the group that was administered the inactivated wild-type virus twice.
Histopathological examination of lung tissue sections revealed that the group that was
administered the inactivated mutant virus twice exhibited significantly thinner alveolar septa,
whereas the thickness of the alveolar septa of the other groups were markedly increased due to
lymphocyte infiltration. These results indicated that the deglycosylation of GP5 enhanced the
immunogenicity of the inactivated mutant PRRSV and that twice administrations of the
inactivated mutant virus conferred better protection against the homologous challenge. These
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findings suggest that the inactivated PRRSV that expresses a hypo-glycosylated GP5 is a potential
inactivated vaccine candidate and a valuable tool for controlling PRRS for the swine industry.
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1. Introduction
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Porcine reproductive and respiratory syndrome (PRRS) is one of the most important
infectious diseases in pigs and is responsible for substantial economic losses in the swine
industry worldwide. The PRRS virus (PRRSV) causes severe reproductive failure in
pregnant sows and is associated with porcine respiratory disease complex (PRDC) in
combination with other viral and bacterial infections in young piglets [1–3]. To help control
outbreaks of PRRS, strategies, such as management, biosecurity and vaccination, have been
applied with various levels of success [4–6]. The control PRRS is complicated due to its
pattern of persistent, subclinical infections with occasional epidemic outbreaks, the great
heterogeneity of the virus and the poor antibody response that is insufficient to completely
block viral re-infection [7–10]. Although the current vaccines need to be improved, and new
vaccine technologies are required, vaccination is the most cost-effective and reliable strategy
that is currently available.
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There are two types of commercially available PRRS vaccines. The first is a modified-live
virus (MLV) vaccine, and the second is an inactivated vaccine. The PRRS MLV vaccine is
well-recognized for its protective efficacy against PRRSV infection in the field, but this
vaccine has a limited efficacy against challenges with heterologous viruses. Additionally,
the PRRS MLV vaccine has an intrinsic risk for reversion to a virulent strain [4]. The PRRS
inactivated vaccine is much safer than the PRRS MLV vaccine. However, this advantage of
the inactivated vaccine is diminished by its insufficient immunogenicity. The commercially
available PRRS inactivated vaccine does not induce a sufficient immune response and does
not adequately protect pigs from viremia when challenged with PRRSVs [11–13]. Although
previous studies have shown that PRRS inactivated vaccines are able to inhibit viral
shedding and induce neutralizing antibodies, these results vary depending on the virus strain
and the type of tissue culture used to produce the vaccines [11,14]. Numerous efforts have
been made to develop an ideal PRRS inactivated vaccine that would offer broad protection
and high immunogenicity [15,16], but these efforts have been unsuccessful.
Previous studies have determined that the neutralizing epitopes are located in the structural
proteins, including glycoprotein (GP) 3, GP4, GP5 and the non-glycosylated membrane
protein (M) [17–19]. Among these, the neutralizing epitopes in GP5 induce the primary
neutralizing antibodies [20–23]. GP5 is encoded by open reading frame (ORF) 5 of the
PRRSV viral genome and is the major envelope glycoprotein of PRRSV. GP5 has been
suggested to be involved in the viral entry and assembly of PRRSV [24]. A small
ectodomain located on the N-terminus of GP5 plays an important role in the attachment of
PRRSV to the macrophage-specific receptor [24,25]. Two epitopes located in this
ectodomain have previously been identified and characterized, based on their neutralizing
Vaccine. Author manuscript; available in PMC 2014 September 02.
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capabilities, as a decoy epitope and a major neutralizing epitope [22]. The delayed
production of neutralizing antibodies to GP5 is a characteristic of the immune response to
PRRSV and is caused by the rapid induction of non-neutralizing antibodies against the
decoy epitope [24,26]. PRRSV-specific non-neutralizing antibodies have been detected at
one week post-inoculation (PI), while neutralizing antibodies have been observed to appear
from three weeks PI [27–29].
The GP5 of PRRSV has two to five potential N-linked glycosylation sites located in the
ectodomain, and the presence of glycans around the major neutralizing epitopes has been
suggested to reduce the immunogenicity of PRRSV [30]. It has been reported that glycan
shielding on PRRSV GPs interferes with the neutralizing antibody response [31–34].
Previous studies have also demonstrated that weak neutralizing antibody responses are
obtained in the presence of glycans on the GPs of other viruses, such as lactate
dehydrogenase-elevating virus, hepatitis B virus, human immunodeficiency virus and
influenza virus [35–38].
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In previous studies, multiple mutants of PRRSV containing various combinations of
deglycosylations on GP5 have been produced using reverse genetics [31,33,39,40]. Among
these mutants, the mutant virus containing a double deglycosylation of N34 and N51 of GP5
shows decreased viral replication but induces a higher level of neutralizing antibodies in in
vivo experiments compared to its parental strain of PRRSV [31]. In this study, we attempted
to develop an inactivated PRRSV vaccine using this mutant strain of PRRSV, which
contains a double deglycosylation of GP5 and evaluated the efficacy of this vaccine using a
challenge infection with a homologous strain of PRRSV.

2. Materials and methods
2.1. cDNA clone, cells and viruses
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A full-length PRRSV infectious cDNA clone (pFL12) generated from the North American
type II PRRSV isolate was used to construct a mutant plasmid carrying mutations in the
putative N-glycosylation sites by site-directed mutagenesis as previously described [41]. To
produce wild-type (wt) and mutant viruses, the pFL12 and mutant plasmids were linearized
by digestion with AclI and transcribed in vitro using the mMESSAGE mMACHINE Ultra
T7 kit (Ambion, Austin, TX). The produced RNAs were electroporated into the MARC-145
cell lines, cultured in low-glucose Dulbecco's Modified Eagle's Medium (DMEM) and
supplemented with 10% fetal bovine serum (FBS) [42] All of the rescued wt and mutant
viruses were subjected to RT-PCR amplification using appropriate primers, and the PCR
fragments were subjected to DNA sequencing to confirm the presence of the desired
mutations and the absence of unwanted mutations. The N-glycosylation profiles of the GP5
for the wt and deglycosylated mutant viruses were confirmed by western blotting. The
viruses were treated for 16 h at 37 °C with the 10 U peptide N-glycosidase F (PNGaseF)
according to the manufacturer's instructions (NEB, Beverly, MA). Subsequently, the
proteins were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred
onto a nitrocellulose membrane (GE Healthcare, Milwaukee, WI). The membrane was
blocked with 5% skim milk in phosphate-buffered saline-Tween 20 and incubated with
porcine serum containing a high level of PRRSV-specific primary antibody and horseradish
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peroxidase-conjugated goat anti-porcine IgG (Southern Biotech, Birmingham, AL)
secondary antibody. The blots were imaged using Amersham ECL Prime Western Blotting
Detection Reagent (GE Healthcare).
2.2. Production of inactivated PRRSV vaccines
Both wt FL12 and the mutant virus FL12/GP5DM containing double-amino acid
substitutions at the 34 and 51 potential N-glycosylation residues in GP5 [31] were used to
produce the inactivated vaccines used in this study.

NIH-PA Author Manuscript

Both the wt and mutant viruses were concentrated at 108 TCID50/ml and inactivated with
binary ethylenimine (BEI) as described previously [43]. Briefly, BEI was prepared as a 0.1
M stock solution by stirring 0.1 M 2-bromoethylamine hydrobromide (Sigma-Aldrich, St.
Louis, MO) in 0.175 M NaOH at 37 °C for 1 h. The BEI stock solution was added to the
virus suspension, and the mixture was incubated at 37 °C for 24 h. The remaining BEI was
subsequently neutralized with 0.1 mM sodium thiosulfate (Sigma-Aldrich) for 2 h. To
confirm the inactivation of the virus, MARC-145 cells were inoculated with BEI-treated
virus suspension and cultured at 37°C for five days. A total of 1 ml of inactivated viral
antigen containing 108 TCID50/ml of the BEI-inactivated PRRSV was mixed with an equal
volume of Montanide™ IMS1313 VG adjuvant (SEPPIC, Paris, France). The aqueous
adjuvant was suitable for inactivated and live vaccines in pigs [44,45].
2.3. Evaluation of the efficacy of the inactivated PRRSV vaccine

NIH-PA Author Manuscript

The experimental design involving the inactivated PRRSV vaccination and the challenge is
summarized in Table 1. Fifteen three-week old piglets were purchased from a PRRS-free
farm and confirmed to be serologically PRRSV-negative. The piglets were randomly
allocated into five groups (G1 to G5). The piglets in G1 and G2 were intramuscularly
administered inactivated wt virus vaccine, and the piglets in G3 and G4 were
intramuscularly administered inactivated mutant virus vaccine. The G5 piglets were injected
with DMEM alone as a control. Three weeks after the primary vaccination, the piglets in G2
and G4 were boost-vaccinated using the same vaccines they had received earlier. Serum
samples were collected at 14, 28, 42, 49 and 56 days post-vaccination and stored in −20 °C.
Five weeks after the booster vaccination, all of the groups were intramuscularly challenged
with 105 TCID50/ml of wt virus. Serum samples were collected at 2, 3, 4, 7, 8, 9 and 13 days
after the challenge. The collected sera were examined for viremia via immunofluorescence
assay in MARC-145 cells. Twenty-one days after the challenge, the pigs were humanely
euthanized according to the guidelines of the Institutional Animal Care and Use Committee
of Konkuk University.
2.4. Serum neutralizing assay
The serum neutralizing (SN) assay was conducted in 96-well plates that contained confluent
MARC-145 cells that had been seeded 48 h before the experiment. Equal volumes of twofold serially diluted serum samples were mixed with 50 μl of 100 TCID50 of the wt virus
and incubated at 37 °C for 1 h. The mixture was applied to a monolayer of MARC-145 cells
and incubated at 37 °C for two days. The cells were fixed and stained with nucleocapsid (N)
protein-specific SDOW17, which was followed by incubation with anti-mouse Alexa Fluor
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488 conjugate (Life Technologies, US). The SN antibody titers are expressed as the
reciprocal of the highest dilution that exhibited a 90% or greater reduction in the number of
fluorescent foci present in the control wells.
2.5. Histopathological examination
The cranial lobes of the lungs were collected from all euthanized animals in postmortem
procedures and fixed in 10% neutral buffered formalin. The fixed tissues were processed for
histopathological examination. The severities of the histopathological lesions were
compared by measuring the thicknesses of the alveolar septa. Fifty hematoxylin and eosinstained sections were randomly selected from each pig, and each section was viewed at 200fold magnification. The thicknesses of the alveolar septa were analyzed with ImageJ
software. The septal thicknesses of at least 50 alveoli per each section were measured by
drawing straight lines across the entire widths of the septa. At least three sections from each
pig were used, and the average septal thickness was then calculated for each group.
2.6. Statistical analyses

NIH-PA Author Manuscript

The SN antibody levels, viremia and microscopic lung lesions were analyzed for significant
differences between groups using Mann–Whitney U tests and Student t-tests that were
performed with SPSS 19 (SPSS, Chicago, IL). A P value less than 0.05 was considered
statistically significant.

3. Results
3.1. Development of the deglycosylated mutant virus and inactivated vaccines
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After genetically engineering the infectious clone pFL12, mutations at the amino acidsites
34 and 51 in GP5 were confirmed by sequencing. The wt virus and the mutant containing
thedouble deglycosylation on GP5 were successfully rescued from the transfected
MARC-145 cells (Fig. S1A). Western blotting revealed that the migration of the GP5 from
the wt virus indicated a mass of 25 kDa, whereas the migration of the GP5 from the mutant
virus indicated a smaller size (20.5 kDa) that nearly overlapped with that of the M envelope
protein. The treatment of the viruses with PNGaseF reduced the sizes of the GP5s to 17 kDa
in both viruses (Fig. S1B). After treatment with BEI, both the wt and mutant viruses did not
induce any detectable cytopathological effects in the MARC-145 cell monolayers over five
days; these results were confirmed by observation under the microscope and by
immunofluorescence staining with the N-specific SDOW17 antibody (data not shown).
3.2. Immune responses of the inactivated vaccines
To determine whether the inactivated PRRSV vaccine containing the mutant virus elicited a
humoral immune response, the piglets were inoculated with the vaccine, and the vaccine's
immunogenicity was assessed. Interestingly, SN antibodies were observed at six weeks postvaccination only in the groups that were inoculated with an inactivated mutant virus (i.e., G3
and G4) (Fig. 1). However, the SN antibodies did not persist for long and were not
detectable at eight weeks post-vaccination (Fig. 1). The SN antibody titer of the group that
was vaccinated twice with the inactivated mutant virus (G4) was much higher and was
maintained for a longer period compared to that of the group that received only the primary
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vaccination (G3). SN antibodies were not observed in either the group that was vaccinated
with the inactivated wt virus (G1 and G2) or the control group (G5).
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3.3. Efficacy of the inactivated vaccines
Five weeks after the boost vaccination, all groups were challenged with the wt virus, and
viremia and SN antibody titers were evaluated. The SN antibodies of the group that was
vaccinated twice with the inactivated mutant virus (G4) was re-evaluated at four days postchallenge, reached a titer of 1:16 at eight days post-challenge and maintained that level until
the end of experiment (Fig. 1). SN antibodies were also detected 10 days post-challenge in
the group that was vaccinated twice with the inactivated wt virus (G2), and these antibodies
reached a titer of 1:8 at 13 days post-challenge. PRRSV-specific SN antibodies were not
detected in the serum samples from the G1, G3 and G5 piglets at any point in the
experimental challenge period.
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Viremia was evident in the four challenged groups (G1–G3, G5) at two dayspost-challenge,
and the G4 piglets exhibited a delayed-onset viremia at three days post-challenge (Fig. 2).
Although the viremia gradually increased and peaked at five days post-challenge in all of the
challenged groups, the magnitude and duration of the viremia in G4 was significantly lower
and shorter than those of other groups. As shown in Fig. 2, the viremia of G4 rapidly
decreased and was undetectable at eight days post-challenge. However, the viremia in the
other groups lasted longer and decreased more gradually until 13 days post-challenge.
The efficacy of the vaccine was investigated using challenge inoculations with a
homologous strain. The piglets that were inoculated with the wt virus exhibited moderate
sneezing and lachrymal discharge. The body weights and rectal temperatures of the piglets
were not significantly different across groups (data not shown). During necropsy, moderate
pneumonic lesions, including severe edema in the lungs and enlargement of the
tracheobronchial lymph nodes, were observed in nearly all of the challenged piglets with the
exception of the G4 piglets (data not shown). Histopathological examination revealed that
all of the piglets in the four groups (G1–G3, G5) exhibited moderate interstitial pneumonia,
significant increases in the thickness of the alveolar septa and lymphocyte infiltrations; in
contrast, the G4 piglets exhibited mild pneumonia, average alveolar septa of 15 μm and
minimal infiltration (Fig. 3).
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4. Discussion
In this study, a mutant virus strain of PRRSV, FL12/GP5DM that possesses deglycosylated
GP5 was created and used to produce an inactivated vaccine. The viruses used to develop
inactivated vaccines were produced using reverse genetics as described in a previous study
[31]. The rescued mutant virus exhibited slightly delayed growth properties compared to the
wt virus (data not shown). Consistent with our results, many mutant viruses have been found
to exhibit reduced viral titers compared with the wt viruses in previous studies [31,46,47]. In
in vivo experiments, the inactivated PRRSV vaccine based on the mutant virus induced a
higher SN antibody titer and resulted in faster clearing of viremia compared to the
inactivated PRRSV vaccine that was based on the wt virus. Moreover, histopathological
examinations revealed that the symptoms of interstitial pneumonia were remarkably reduced
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in the group that was vaccinated with the inactivated mutant virus. While microscopic
observation revealed obvious lymphocyte infiltration and interstitial pneumonia in all other
groups, the markedly thin alveolar septa and lack of or minimal infiltration in G4 clearly
indicated that the inactivated vaccine prepared with the mutant virus effectively protected
the piglets from a homologous challenge infection.
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A possible explanation for this effect of the hypo-glycosylated PRRSV has been provided in
previous studies; this explanation postulates that the deglycosylation of GP3 and/or GP5
enhances the immunogenicity of a live virus despite decreasing the replication of the mutant
viruses to some extent [31,33,34,39,40]. These results revealed that the removal of glycans
from either GP3 or GP5 might expose hidden neutralizing epitope(s) and can improve SN
antibody responses. The present study demonstrated that the deglycosylation of GP5 also
successfully improved the immunogenicity of an inactivated virus that was incapable of
viral replication and endogenous viral protein synthesis to a level similar to that of a live
virus. In previous studies, enhanced developments of SN antibodies have not always been
associated with blocking viremia [48,49]. However, Osorio et al. [50] previously
demonstrated that the SN antibody response is relatively correlated with protective
immunity in PRRSV infection, particularly regarding the clearance of viremia; our results
are in agreement with their findings [50].
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Inactivated PRRSV vaccines are well-known to induce insufficient protective immune
responses against both homologous and heterologous PRRSV challenges [12,51]. In this
study, an inactivated mutant virus vaccine elicited a considerable increase in the level of SN
antibodies following vaccination, whereas the inactivated wt virus vaccine did not induce
SN antibodies prior to the challenge (Fig. 1). As the extent of our knowledge, this is the first
report to show that a single intramuscular administration of inactivated PRRSV vaccine can
induce detectable humoral immune responses. Although both G3 and G4 exhibited SN
antibody induction following vaccination, only G4 received a boost vaccination, which reinduced high levels of SN antibodies following the challenge. After the challenge with the
wt virus, a PRRSV-specific SN antibody response was evident in the G4 piglets. The SN
antibody titer had quickly increased again by four days post-challenge and was maintained
at a titer of 1:16 until the end of the experiment. These results indicate that a boost
vaccination of the inactivated PRRSV vaccine is necessary to induce a sufficient humoral
immune response. In a previous study that utilized a commercially inactivated vaccine, a
clear anamnestic humoral immune response was observed following a heterologous
challenge with wt virus, but this response was much slower and weaker than that observed
in G4 [13]. Compared to the unvaccinated pigs, the G4 piglets exhibited a significantly
delayed onset of viremia and subsequently rapidly cleared the viremia; these results are
consistent with those of previous studies [12,52]. The inactivated vaccine containing the
FL12/GP5DM strain was able to induce an SN antibody response after a single
intramuscular administration and significantly reduced lung pathology, whereas the
inactivated vaccine used in a previous study failed to induce an efficacious humoral immune
response [13]. Although our observations are, on the one hand, in agreement with findings
of the authors of this previous study that an inactivated vaccine can induce a humoral
immune response after a challenge, on the other hand, these authors postulated that the postchallenge anamnestic response comprised of PRRSV-specific SN antibodies was not
Vaccine. Author manuscript; available in PMC 2014 September 02.
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sufficient to provide humoral immunity based on the viremia and viral loads these authors
detected in the tissues during the post-challenge period. However, a direct comparison
between these two findings is not relevant because we used a tissue culture method to detect
viable viruses, and the authors of the other study used quantitative PCR to detect the
presence of any viral RNA. Furthermore, we did not observe anamnestic responses in the
groups that were inoculated once (G1 and G3), which contrasts with the previous findings;
however, we did observe this response in the groups that were inoculated twice. It is also not
appropriate to conclude that the co-existence of SN antibodies and viral RNA constitutes
evidence of ineffective protection unless other parameters of protective efficacy, such as
clinical outcome, lung pathology and cell-mediated immunity, are considered. Nonetheless,
our findings indicated that the inactivated vaccine is capable of inducing a sustained SN
antibody response following the vaccination and enhancing the memory response after the
challenge when the inactivated vaccine is suitably formulated with a benign
immunostimulating adjuvant and applied according to proper vaccination regimen. These
results suggest that the inactivated vaccine we produced with a mutant virus that possesses a
hypo-glycosylated GP5 may be a promising alternative PRRSV vaccine that is capable of
inducing humoral immune responses that are comparable to those induced by MLV in the
field; this alternative vaccine may be particularly useful in areas and countries in which the
use of the live virus vaccine is not feasible.
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It has been speculated that the efficacy of an inactivated vaccine is potentiallydetermined by
the inactivation agent and/or the adjuvant [52–54]. In this study, the BEI-inactivated vaccine
successfully induced the SN antibody response and partially inhibited viremia. These results
are consistent with the results of the previous study that used a BEI-inactivated vaccine [52].
In this previous study, BEI was used as an inactivating reagent instead of formaldehyde,
which is generally the most widely used reagent in such cases. The inactivating reagent and
method may affect the efficacies of inactivated vaccines and should be strongly considered
during the development of inactivated vaccines. BEI was used to inactivate the virus due to
its specific effects on the viral genome that do not damage the viral epitopes [55]. In a
previous study, BEI was found to have a minimal slight effect on the epitopes, whereas
formaldehyde substantially alters the conformations of the epitopes [56]. BEI is the most
promising of the methods of inactivating PRRSV, which include the following: gamma
irradiation, formaldehyde, UV modification, and pH modification. BEI has successfully
been used to inactivate PRRSV in previous studies [52,57,58]. In these previous studies,
inactivated PRRSV vaccine induced effective immune responses after single intranasal
administrations [53,54]. However, the intranasal vaccine delivery route requires an
additional vaccine spray machine and has to be performed by well-trained staff. Currently,
vaccines that can be administered via the intramuscular route and are composed of an oil
adjuvant and inactivated with BEI are the most popular type of inactivated vaccine with the
pig industry [52].
In summary, the double amino acid substitutions at the N-glycosylated sites near the major
neutralizing epitope in GP5 remarkably increased the immunogenicity of PRRSV,
particularly in terms of the SN antibody response, and rapidly reduced the viral loads in the
sera. The mutant virus FL12/GP5DM was able to act as an inactivated vaccine candidate
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against PRRSV. Although a single administration of the inactivated PRRSV vaccine based
on the mutant virus induced a humoral immune response, a boost administration is
recommended to ensure efficacy. A variety of additional adjuvants that may improve the
immune response to KV vaccines should be considered in further studies.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. PRRSV-specific SN antibody titers following vaccination and challenge

Piglets were injected once with wt virus (G1), twice with wt virus (G2), once with mutant
virus (G3), twice with mutant virus (G4), or sterile media (G5). The levels of serum
neutralizingantibodies against PRRSV were measured using the wt virus and MARC-145.
Asterisks indicate significant differences (P < 0.05) compared to the control group (G5).
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Fig. 2. Viremia in the sera following challenge

The piglets were challenged following vaccination, and viremia was measured at different
times. The piglets were injected once with wt virus (G1), twice with wt virus (G2), once
with mutant virus (G3), twice with mutant virus (G4), or sterile media (G5). Asterisks
indicate significant differences (P < 0.05) compared to the control group (G5).
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Fig. 3. Histopathological examination

The graph depicts the thicknesses of the alveolar septa (A), and the photomicrographs (B)
show hematoxylin and eosin-stained sections of the cranial lobes of the lungs following the
in vivo experiments. The piglets were injected once with wt virus (G1, a), twice with wt
virus (G2, b), once with mutant virus (G3, c), twice with mutant virus (G4, d), or sterile
media (G5, e). Asterisks indicate significant differences (P < 0.05) between the indicated
pairs of groups. The arrows indicate the localized regions of severe interstitial pneumonia
and thickened alveolar septa. Magnification: ×200.
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In vivo experimental design.
Groups

Number of piglets

Vaccination (inactivated virus vaccines)
1st

2nd

Challenge virus (FL12)

G1

3

+ (FL12)

–

+

G2

3

+ (FL12)

+ (FL12)

+

G3

3

+ (FL12/GP5DM)

–

+

G4

3

+ (FL12/GP5DM)

+ (FL12/GP5DM)

+

G5

3

–

–

+
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